Immunotherapy dominated by programmed death‐1/programmed death‐ligand 1 (PD‐1/PD‐L1) checkpoint inhibitors has recently emerged as a standard of treatment for advanced‐stage NSCLC.[25] These ICI therapies aim to enhance local immune response against tumor by means of disrupting the binding of PD‐1 on the T‐cell surface and PD‐L1 on the tumor cell surface and restricting PD‐1/PD‐L1‐mediated T‐cell suppression. This evidence concerns the gene CD274 and non-small cell lung carcinoma.